Supernus Pharmaceuticals Inc. (Nasdaq: SUPN) has eliminated a lower dose option of its Phase 3 clinical trial of SPN-810 to treat impulsive aggression in patients aged 6 to 12 years who have attention deficit hyperactivity disorder. The stock price plunged $11.60 to close at $38.05.
